The purpose of this study is to assess the Safety, Tolerability and Efficacy of ZD6126 in Combination with Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects with Metastatic Colorectal Cancer.

Inclusion Criteria:

• Metastatic colorectal carcinoma
• Suitable for first-line treatment of metastatic disease

Exclusion Criteria:

• Peripheral neuropathy greater than Grade 1
• Adjuvant therapy within 6 months prior to study treatment
• Prior oxaliplatin
• Prior pelvic or whole abdomen radiation
• Any history of coronary angioplasty or history of myocardial infarction